In Reply We thank Anderson for carefully reviewing our work1 and taking time to share his concerns about the classification of pseudoephedrine together with other medications that inhibit the reuptake of serotonin. We underscore that this classification is correct per 2 reputable pharmacological resources exploited in our article, DrugBank.ca2 and PubChem.com.3 Nevertheless, we also fully acknowledge that the medication is reported to have weak affinity to serotonin transporter.4 Although our method entailed inclusion of drugs with different affinities for any one target, below we explain how this impacted our findings and outline potential extensions of our method related to Anderson’s letter.
Janecka M, Sandin S, Reichenberg A. Autism Risk and Serotonin Reuptake Inhibitors—Reply. JAMA Psychiatry. 2019;76(5):548–549. doi:10.1001/jamapsychiatry.2019.0081
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.